DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04520451 (ClinicalTrials.gov)	August 21, 2020	11/8/2020	Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients	An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease	IgG4-Related Disease	Drug: rilzabrutinib;Drug: Glucocorticoids	Principia Biopharma Inc.	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	25	Phase 2	United States
2	ChiCTR2000028918	2020-01-01	2020-01-07	A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases	Efficacy and safety of thalidomide in IgG4-related diseases	IgG4 related disease	control group:prednison combined with placebo;experimental group:prednison combined with thalidomide;	Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	NULL	Recruiting	18	80	Both	control group:51;experimental group:51;	Phase 4	China
3	NCT01758393 (ClinicalTrials.gov)	December 2012	24/12/2012	Glucocorticoids in Patients With IgG4-RD	A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease	IgG4-related Disease	Drug: Prednisone	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	70 Years	Both	40	Phase 2;Phase 3	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04520451
(ClinicalTrials.gov)

August 21, 2020

11/8/2020

Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients

An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease

IgG4-Related Disease

Drug: rilzabrutinib;Drug: Glucocorticoids

Principia Biopharma Inc.

Massachusetts General Hospital

Recruiting

18 Years

N/A

All

Phase 2

United States

ChiCTR2000028918

2020-01-01

2020-01-07

A randomized, double-blind controlled study of glucocorticoids combination with thalidomide in the treatment of IgG4-related diseases

Efficacy and safety of thalidomide in IgG4-related diseases

IgG4 related disease

control group:prednison combined with placebo;experimental group:prednison combined with thalidomide;

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

NULL

Recruiting

Both

control group:51;experimental group:51;

Phase 4

China

NCT01758393
(ClinicalTrials.gov)

December 2012

24/12/2012

Glucocorticoids in Patients With IgG4-RD

A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease

IgG4-related Disease

Drug: Prednisone

Peking Union Medical College Hospital

NULL

Recruiting

18 Years

70 Years

Both

Phase 2;Phase 3

China